JYNT vs. CRDF, VERU, ATOS, AKYA, INMB, ALIM, PROF, MASS, ABOS, and SMLR
Should you be buying Joint stock or one of its competitors? The main competitors of Joint include Cardiff Oncology (CRDF), Veru (VERU), Atossa Therapeutics (ATOS), Akoya Biosciences (AKYA), INmune Bio (INMB), Alimera Sciences (ALIM), Profound Medical (PROF), 908 Devices (MASS), Acumen Pharmaceuticals (ABOS), and Semler Scientific (SMLR). These companies are all part of the "medical" sector.
Cardiff Oncology (NASDAQ:CRDF) and Joint (NASDAQ:JYNT) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, risk, earnings, dividends, media sentiment, analyst recommendations, institutional ownership, profitability and community ranking.
Joint received 240 more outperform votes than Cardiff Oncology when rated by MarketBeat users. Likewise, 62.25% of users gave Joint an outperform vote while only 61.67% of users gave Cardiff Oncology an outperform vote.
Cardiff Oncology currently has a consensus price target of $10.50, suggesting a potential upside of 163.16%. Joint has a consensus price target of $21.50, suggesting a potential upside of 77.98%. Given Joint's stronger consensus rating and higher probable upside, research analysts plainly believe Cardiff Oncology is more favorable than Joint.
In the previous week, Cardiff Oncology and Cardiff Oncology both had 2 articles in the media. Cardiff Oncology's average media sentiment score of 0.00 beat Joint's score of -0.50 indicating that Joint is being referred to more favorably in the news media.
Joint has a net margin of -8.19% compared to Joint's net margin of -8,492.01%. Cardiff Oncology's return on equity of 7.80% beat Joint's return on equity.
Cardiff Oncology has a beta of 1.94, suggesting that its stock price is 94% more volatile than the S&P 500. Comparatively, Joint has a beta of 1.59, suggesting that its stock price is 59% more volatile than the S&P 500.
16.3% of Cardiff Oncology shares are held by institutional investors. Comparatively, 76.9% of Joint shares are held by institutional investors. 6.3% of Cardiff Oncology shares are held by insiders. Comparatively, 4.0% of Joint shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Joint has higher revenue and earnings than Cardiff Oncology. Joint is trading at a lower price-to-earnings ratio than Cardiff Oncology, indicating that it is currently the more affordable of the two stocks.
Summary
Joint beats Cardiff Oncology on 10 of the 17 factors compared between the two stocks.
Get Joint News Delivered to You Automatically
Sign up to receive the latest news and ratings for JYNT and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding JYNT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
